Geoff Meacham
Stock Analyst at Citigroup
(4.32)
# 394
Out of 5,138 analysts
283
Total ratings
60%
Success rate
13.36%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Initiates: Buy | $55 | $46.53 | +18.20% | 1 | Jan 9, 2026 | |
| VOR Vor Biopharma | Initiates: Buy | $50 | $14.06 | +255.62% | 1 | Jan 9, 2026 | |
| BIIB Biogen | Maintains: Neutral | $153 → $180 | $168.57 | +6.78% | 17 | Jan 7, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $135 → $140 | $121.26 | +15.45% | 8 | Jan 7, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $95 → $110 | $110.97 | -0.87% | 9 | Jan 7, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $110 | $71.12 | +54.67% | 7 | Dec 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $98 → $115 | $84.75 | +35.69% | 4 | Dec 8, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $58 → $49 | $13.72 | +257.14% | 3 | Dec 2, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $26 | $25.89 | +0.42% | 7 | Dec 2, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.86 | +330.11% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $75.64 | -0.85% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $235 | $216.75 | +8.42% | 21 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $741.92 | -5.65% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $72 | $72.60 | -0.83% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $39.36 | -28.86% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $31.83 | +57.08% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $37.92 | +31.86% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $13.52 | +47.93% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $54.21 | +71.56% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $438.92 | +31.00% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $6.20 | +125.81% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $305 → $310 | $330.03 | -6.07% | 13 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $39.72 | +5.74% | 3 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $76.26 | -29.19% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $68.32 | +61.01% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $7.78 | -22.88% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $106.07 | +31.99% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.13 | -53.05% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $80.75 | +17.65% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $55.07 | +87.03% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.91 | +109.42% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $1,032.97 | +6.49% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $22.93 | -12.78% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $29.02 | +6.82% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $219.57 | -22.58% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $56.62 | +5.97% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.39 | +1,123.02% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.58 | +1,418.99% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $12.21 | -67.24% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $9.56 | +192.89% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.30 | +1,378.26% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.13 | +1,018.21% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $23.95 | +2,092.07% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.14 | +3,584.21% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.69 | +160.08% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.43 | +4,551.16% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $6.38 | +41.07% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $13.76 | +336.05% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $23.63 | -2.67% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $105.24 | -22.08% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $471.99 | -79.87% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $18.80 | +325.53% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $133.35 | +1.24% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.26 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.52 | +342.48% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $11.92 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $359.26 | -56.02% | 5 | Nov 8, 2017 |
Scholar Rock Holding
Jan 9, 2026
Initiates: Buy
Price Target: $55
Current: $46.53
Upside: +18.20%
Vor Biopharma
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $14.06
Upside: +255.62%
Biogen
Jan 7, 2026
Maintains: Neutral
Price Target: $153 → $180
Current: $168.57
Upside: +6.78%
Gilead Sciences
Jan 7, 2026
Maintains: Buy
Price Target: $135 → $140
Current: $121.26
Upside: +15.45%
Merck & Co.
Jan 7, 2026
Maintains: Neutral
Price Target: $95 → $110
Current: $110.97
Upside: -0.87%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $71.12
Upside: +54.67%
Protagonist Therapeutics
Dec 8, 2025
Maintains: Buy
Price Target: $98 → $115
Current: $84.75
Upside: +35.69%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $13.72
Upside: +257.14%
Pfizer
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $25.89
Upside: +0.42%
Acumen Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.86
Upside: +330.11%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $75.64
Upside: -0.85%
Nov 3, 2025
Maintains: Neutral
Price Target: $240 → $235
Current: $216.75
Upside: +8.42%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $741.92
Upside: -5.65%
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $72.60
Upside: -0.83%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $39.36
Upside: -28.86%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $31.83
Upside: +57.08%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $37.92
Upside: +31.86%
Oct 17, 2025
Maintains: Buy
Price Target: $12 → $20
Current: $13.52
Upside: +47.93%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $54.21
Upside: +71.56%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $438.92
Upside: +31.00%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $6.20
Upside: +125.81%
Aug 6, 2025
Maintains: Neutral
Price Target: $305 → $310
Current: $330.03
Upside: -6.07%
Jul 22, 2025
Maintains: Buy
Price Target: $40 → $42
Current: $39.72
Upside: +5.74%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $76.26
Upside: -29.19%
Jun 17, 2025
Initiates: Buy
Price Target: $110
Current: $68.32
Upside: +61.01%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $7.78
Upside: -22.88%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $106.07
Upside: +31.99%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.13
Upside: -53.05%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $80.75
Upside: +17.65%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $55.07
Upside: +87.03%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.91
Upside: +109.42%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $1,032.97
Upside: +6.49%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $22.93
Upside: -12.78%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $29.02
Upside: +6.82%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $219.57
Upside: -22.58%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $56.62
Upside: +5.97%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.39
Upside: +1,123.02%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.58
Upside: +1,418.99%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $12.21
Upside: -67.24%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $9.56
Upside: +192.89%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.30
Upside: +1,378.26%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.13
Upside: +1,018.21%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $23.95
Upside: +2,092.07%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.14
Upside: +3,584.21%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.69
Upside: +160.08%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.43
Upside: +4,551.16%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $6.38
Upside: +41.07%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $13.76
Upside: +336.05%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $23.63
Upside: -2.67%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $105.24
Upside: -22.08%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $471.99
Upside: -79.87%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $18.80
Upside: +325.53%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $133.35
Upside: +1.24%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $9.26
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.52
Upside: +342.48%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $11.92
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $359.26
Upside: -56.02%